COMMUNIQUÉS West-GlobeNewswire
-
Lumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPES 2024
25/09/2024 - 22:05 -
PreAnalytiX, a QIAGEN and BD joint venture, launches novel solution for liquid biopsy from urine samples
25/09/2024 - 22:05 -
BioVie Inc. Announces Closing of Public Offering
25/09/2024 - 22:05 -
MDxHealth Announces Launch of Offering of Ordinary Shares
25/09/2024 - 22:05 -
Lifecore Biomedical to Participate at Upcoming Industry Conferences and Events
25/09/2024 - 22:05 -
Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024
25/09/2024 - 22:30 -
Certara’s Simcyp Consortium Celebrates 25th Anniversary
24/09/2024 - 14:00 -
First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center
24/09/2024 - 14:00 -
Standard BioTools Achieves New Record of the Most Protein Measurements on the Most Sample Types with Expansion of the SomaScan® 11K Platform
24/09/2024 - 14:00 -
Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
24/09/2024 - 14:00 -
Starton Therapeutics’ Chief Executive Officer Chosen as 2024 Honoree by the Icla da Silva Foundation
24/09/2024 - 14:00 -
FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
24/09/2024 - 14:00 -
Spectral AI Achieves 25% Patient Enrollment at Emergency Departments for U.S. Burn Pivotal Study and Adds Two New Clinical Trial Sites
24/09/2024 - 14:00 -
Nectero Medical Recognized as a 2024 AZBio Fast Lane Award Winner
24/09/2024 - 14:00 -
TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to “SCNX”
24/09/2024 - 14:01 -
Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results
24/09/2024 - 14:01 -
Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
24/09/2024 - 14:30 -
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
24/09/2024 - 14:30 -
CytoDyn Announces Preliminary Findings in Study with SMC Laboratories
24/09/2024 - 14:30
Pages